| An Open-lable, Multicenter, expanded access study of INC424 for patients with primary myelofibrosis (PMF) or post polycythemia myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibrosis (PET-MF). |
Completed |
INC424 (ruxolitinib) |
3b |
CINC424A2401 |
NGHA-R |
| AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS |
Terminated |
Ocrelizumab |
3b |
MN39159 |
KFSH&RC-R |
| An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension |
Ongoing |
Interferon beta-1a |
3 |
105MS306 |
KFSH&RC-J |
| An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension |
Ongoing |
Interferon beta-1a |
3 |
105MS306 |
KFSH&RC-J |
| An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) |
Terminated |
NIVOLUMAB IPILIMUMAB |
3 |
CA209-227 |
KFSH & RC-R |
| An Open-Label, Pharmacokinetic and Safety Study of Travoprost Ophthalmic Solution, 0.004% in Pediatric Glaucoma or Ocular Hypertension Patients |
Completed |
Travoprost 0.004% |
1 |
C-12-009 |
KKESH |
| "An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfotase Alfa (human recombinant tissue non-specific alkaline phosphatase fusion protein) in Infants and Children ≤ 5 Years of Age with Hypophosphatasia (HPP). " |
Completed |
Asfotase Alfa |
2 |
ENB-010-10 |
KFSH & RC-R |
| An open-Label, multicenter, expanded access study of Everolimus in Patients with advanced Nerouendocrine tumors. |
Completed |
Everolimus |
3b |
CRAD001K24133 |
KFSH & RC-R |
| An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I) |
Ongoing |
ABT-450/r/ABT-267+ABT-333 (-/+) Ribavirin (RBV) |
3b |
M14-423 |
KKUH |
| An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of A4250 in Children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 2) |
Ongoing |
A4250 |
3 |
A4250-008 |
KFSH&RC-R |
